News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AngioChem Announces Plans for Advancing Product Candidates from Proprietary Platform



12/8/2010 8:46:45 AM

MONTREAL--(BUSINESS WIRE)--Angiochem, Inc. today announced its plans for advancing the development of product candidates from its pipeline, using the company’s proprietary platform for Engineered Peptide Compounds (EPiC) for drugs that cross the blood-brain barrier through LRP-1 targeting. The product candidates cover a range of therapeutic areas, including pain, obesity and Parkinson’s disease, using Angiochem’s technology to uniquely enable drugs to penetrate the CNS, including biologics (peptides and proteins) and small molecules. In addition, Angiochem will continue to actively pursue additional research and development collaborations.

Read at BioSpace.com


comments powered by Disqus
AngioChem
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES